CAMBRIDGE, Mass., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, announced today that Paul Bolno, MD, MBA, President and Chief Executive Officer, is scheduled to give a pre-recorded presentation at the H.C. Wainwright 23rd Annual Global Investment Conference, which will be made available for on-demand viewing on Monday, September 13, 2021 at 7:00 a.m. ET.

A webcast of the presentation will be available on the Investor Relations page of the Wave Life Sciences corporate website at http://ir.wavelifesciences.com. A replay of the presentation will be archived and available at that site for 90 days following the event.

About Wave Life Sciences 
Wave Life Sciences (Nasdaq: WVE) is a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases. Wave aspires to develop best-in-class medicines across multiple therapeutic modalities using PRISM, the company’s proprietary discovery and drug development platform that enables the precise design, optimization, and production of stereopure oligonucleotides. Driven by a resolute sense of urgency, the Wave team is targeting a broad range of genetically defined diseases so that patients and families may realize a brighter future. To find out more, please visit www.wavelifesciences.com and follow Wave on Twitter @WaveLifeSci.

Investor Contact:
Kate Rausch
617-949-4827
krausch@wavelifesci.com 

Media Contact:
Alicia Suter
617-949-4817
asuter@wavelifesci.com 


Primary Logo